Related references
Note: Only part of the references are listed.A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer
Neil Vasan et al.
CLINICAL CANCER RESEARCH (2014)
EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysis
Qiong Zhang et al.
LUNG CANCER (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
Monic Roengvoraphoj et al.
CANCER TREATMENT REVIEWS (2013)
Determinants of Survival in Advanced Non-Small-Cell Lung Cancer in the Era of Targeted Therapies
Joshua Bauml et al.
CLINICAL LUNG CANCER (2013)
Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Tanja Cufer et al.
EUROPEAN JOURNAL OF CANCER (2013)
KRAS Mutation: Should We Test for It, and Does It Matter?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
Chen Mao et al.
LUNG CANCER (2010)
The molecular pathology of cancer
Timothy J. R. Harris et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Jaume Capdevila et al.
CANCER TREATMENT REVIEWS (2009)
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Yohann Loriot et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
